- Home
- BP vs BMY Comparison
BP vs BMY Comparison
Compare BP & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BP | BMY |
|---|---|---|
| Founded | 1889 | 1887 |
| Country | United Kingdom | United States |
| Employees | N/A | 32500 |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.5B | 123.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BP | BMY |
|---|---|---|
| Price | $42.68 | $59.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 15 |
| Target Price | $40.89 | ★ $61.93 |
| AVG Volume (30 Days) | ★ 9.9M | 9.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.64% | 4.28% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.19 | N/A |
| Revenue Next Year | $0.79 | N/A |
| P/E Ratio | $11,332.35 | ★ $17.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.22 | $42.52 |
| 52 Week High | $42.48 | $62.89 |
Technical Indicators
Market Signals| Indicator | BP | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 71.79 | 45.35 |
| Support Level | $33.43 | $53.88 |
| Resistance Level | N/A | $62.47 |
| Average True Range (ATR) | 0.83 | 1.16 |
| MACD | 0.32 | -0.51 |
| Stochastic Oscillator | 97.21 | 13.25 |
Price Performance
Historical ComparisonAbout BP BP p.l.c.
BP is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, it produced 1.2 million barrels of liquids and 6.9 billion cubic feet of natural gas per day. At the end of 2024, reserves stood at 6.2 billion barrels of oil equivalent, 59% of which are liquids. The company operates refineries with a capacity of 1.6 million barrels of oil per day.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.